Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
Ingelheim, Germany, 17 March 2011 – A new label claim for Boehringer Ingelheim’s pig vaccine Ingelvac MycoFLEX® has been approved in Europe allowing its mixing with the world leading PCV-2 vaccine Ingelvac CircoFLEX®. The label variation for Ingelvac MycoFLEX® completes a process in which Ingelvac CircoFLEX® had received a corresponding mixing claim by the European Commission already in July 2010.
Boehringer Ingelheim is marketing the unique flexible concept of combinable stand alone vaccines against PCV2/Mycoplasma hyopneumoniae under the name FLEXcombo®.
Mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® allows the protection of pigs against two of the most prominent and costly diseases more conveniently than in the past, using only one injection instead of up to four injections. This provides several benefits in animal welfare (less stress for pigs), farm economics (saving labour) and animal health (fewer chances for pathogen transfer via injection needles).
Boehringer Ingelheim - The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 Years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com